Another type, which is negative for estrogen receptor (ER), progesterone receptor (PR), and HER-2—all used as biomarkers in breast cancer treatment—is defined as the triple-negative breast cancer (TNBC) [8]. This evidence concerns the gene ERBB2 and breast carcinoma.